Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: Ten years experience of 50 patients

Acta Dermato-Venereologica

Volumn 77, Issue 5, 1997, Pages 379-381

  Sasaki, Yuko ^a   Shimizu, Hiroshi ^a   Naka, Wataru ^a   Takeshita, Eiko ^a   Nishikawa, Takeji ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Malignant melanoma; Metastasis; Precursor of pheomelanin; Prognosis

Indexed keywords

CYSTEINYLDOPA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; URINARY EXCRETION; URINE LEVEL;

ADULT; AGED; CYSTEINYLDOPA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PHYSICAL EXAMINATION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030929039     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Prota G. Recent advances in the chemistry of melanogenesis in mammals. J Invest Dermatol 1980; 75: 122-127.
2. Rorsman H, Rosengren AM, Rosengren E. Determination of 5-S-cysteinyldopa in melanomas with a fluorimetric method. Yale J Biol Med 1973; 46: 516-522.
3. Peterson LL, Woodward WR, Fletcher WS, Palmquist M, Tucker MA, Ilias A. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. J Am Acad Dermatol 1988; 19: 509-515.
4. Hara H, Chino K, Kawanami T, Sameshima T, Morishima T. 5-S-cysteinyldopa in urine and tumors. J Dermatol 1992; 19: 806-808.
5. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73: 629-636.
6. Agrup G, Falck B, Fyge K, Rorsman H, Rosengren AM, Rosengren E. Excretion of 5-S-cysteinyldopa in the urine of healthy subjects. Acta Derm Venereol (Stockh) 1975; 55: 7-9.
7. Aubert C, Rosengren E, Rorsman H, Rouge F, Foa C, Lipcey C. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations. Eur J Cancer 1977; 13: 1299-1308.
8. Agrup G, Agrup P, Andersson T, Falck B, Hansson JA, Jacobsson S, et al. 5-S-cysteinyldopa in the urine of melanoma patients. Acta Derm Venereol (Stockh) 1977; 57: 113-116.
9. Agrup G, Agrup P, Andersson T, Hafström L, Hansson C, Jacobsson S, et al. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis. Acta Derm Venereol (Stockh) 1979; 59: 381-388.
10. Riggin R. Determination of catecholamins in urine by reversed-phase liquid chromatography with electrochemical detection. Anal Chem 1977; 49: 2109-2111.
11. Morishima T, Saito M, Hanawa S. Quantitative determination of 5-S-cysteinyldopa, dopa and dopamine in the urine by means of high-performance liquid chromatography. A comparison with data obtained by means of fluorometry. J Dermatol 1981; 8: 301-304.
12. Kågedal B, Pettersson A. Determination of urinary 5-S-cysteinyldopa by high-performance liquid chromatography. J Chromatogr 1983; 272: 287-297.
13. Ito S, Kato T, Fujita K. Seasonal variation in urinary excretion of 5-S-cysteinyldopa in healthy Japanese. Acta Derm Venereol (Stockh) 1987; 67: 163-165.